LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1657 | 5087 | 5383 | 0.9459 | 0.9359 |
SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1506 | 3643 | 0.4131 | 0.0126 |
BT-20 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1657 | 4854 | 5383 | 0.9034 | 0.8832 |
MDA-MB-231 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2182 | 3556 | 0.6146 | 0.5740 |
MCF7 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3186 | 4056 | 0.7852 | 0.7355 |
Hs 578T | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 929 | 3030 | 3216 | 0.9421 | 0.9342 |
MCF 10A | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 513 | 351 | 10473 | 0.0335 | -0.0847 |
MDA-MB-231 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 868 | 2948 | 3556 | 0.8290 | 0.8237 |
SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1484 | 3643 | 0.4075 | 0.0023 |
Hs 578T | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 929 | 3002 | 3216 | 0.9333 | 0.9243 |
Hs 578T | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 929 | 3069 | 3216 | 0.9542 | 0.9483 |
MCF7 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 2830 | 4056 | 0.6983 | 0.6221 |
MDA-MB-231 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 2549 | 3556 | 0.7165 | 0.6971 |
SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1371 | 3643 | 0.3762 | -0.0579 |
MCF7 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 2890 | 4056 | 0.7125 | 0.6409 |
SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1324 | 3643 | 0.3644 | -0.0802 |
MDA-MB-231 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 868 | 2626 | 3556 | 0.7383 | 0.7222 |
MDA-MB-231 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 868 | 2774 | 3556 | 0.7803 | 0.7690 |
MCF7 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1235 | 664 | 4056 | 0.1637 | -0.3041 |
MCF7 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3301 | 4056 | 0.8145 | 0.7745 |
BT-20 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1657 | 1569 | 5383 | 0.2917 | -0.0317 |
Hs 578T | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 929 | 2985 | 3216 | 0.9281 | 0.9179 |
MDA-MB-231 | Alpelisib | 3.33 | uM | LJP5 | 72 | hr | 868 | 3000 | 3410 | 0.8798 | 0.8743 |
BT-20 | Alpelisib | 3.33 | uM | LJP5 | 72 | hr | 1657 | 2120 | 5588 | 0.3796 | 0.1505 |
SK-BR-3 | Alpelisib | 10 | uM | LJP5 | 72 | hr | 1476 | 1181 | 3772 | 0.3133 | -0.1523 |